北京若生智能科技有限公司
Drug Database
CE

cetirizine (QZYTIR / JDP207 / Quzyttir)

✓ Approved

Hospira Inc · HRH1 · 小分子

什么是 cetirizine？

cetirizine 是一种小分子，由Hospira Inc研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection、Intravenous (IV)。

药物档案

商品名QZYTIR, JDP207, Quzyttir
公司Hospira Inc
药物类别小分子
分子靶点HRH1
给药途径Injectable (Others), Intramuscular (IM) Injection, Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Hospira Inc

作用机制

分子靶点

cetirizine 作用于 1 个分子靶点：

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cetirizine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersUrticaria✓ Approved

相关研究文献

PubMedJournal of dental sciences2026-10-25

A scientometric study on research trends and characteristics of Kimura disease.

Lv Zhongjing Z, Luo Yiming Y, Liu Wei W, Yuan Jian J

Kimura disease (KD) is an idiopathic condition that presents as a chronic, benign inflammatory disorder, typically affecting the head and neck region. The purpose of this study was to analyze the scientometric characteristics and research trends of KD. All the papers on KD were comprehensively retrieved from the Scopus database. The years of publication were divided into before 2012 and after 2012 in the analysis of research trends. There were 925 papers on KD, with total citations of 10,821 and the h index of 47. Eosinophilia, lymphadenopathy, nephrotic syndrome, angiofollicular lymph node hyperplasia, swelling, pruritus, proteinuria, eosinophilic granuloma, hypereosinophilia, subcutaneous nodule, asthma, edema, membranous glomerulonephritis were KD-related conditions. The trend of investigations has changed to CD20 antigen, creatinine, cheek, excisional biopsy, diagnostic imaging, positron emission tomography-computed tomography (PET-CT), abscess, erythema, membranous glomerulonephritis, IgG4 related disease, exophthalmos, hypertension, and complication after 2012. The trend of treatment has changed to adrenal cortex hormones, methylprednisolone, mycophenolate mofetil, methotrexate, cetirizine, monoclonal antibody, dupilumab, and drug withdrawal after 2012. There have always been common keywords such as pathology, immunoglobulin blood level, IgE, IgG, interleukin-4, eosinophil count, computer assisted tomography, magnetic resonance imaging, cervical lymph node, and head and neck. This scientometric study for the first time elucidated the current scenario and research trends of KD, and would help in improving in reciprocal collaboration and communication for investigations on this disease.

PMID 42924188
阅读全文 →
PubMedFrontiers in cardiovascular medicine2026-10-24

Case Report: Recurrent Kounis syndrome complicated with acute coronary stent thrombosis.

Li Yong Y, Jiang Chuanwen C, Zhou Xiaojun X, Cao Qidong Q

Kounis syndrome manifests as an acute coronary syndrome induced by an allergic or hypersensitivity reaction. Kounis syndrome consists of three types: Type I is characterized by coronary artery spasm in normal or near-normal arteries, Type II by the rupture of coronary artery plaques, and Type III by the formation of thrombus within the coronary artery stent. Recurrent episodes of Kounis syndrome are uncommon in clinical practice. We herein report a case of recurrent Kounis syndrome, in which the second episode presented as Type III Kounis syndrome. We report a patient who experienced two acute coronary events triggered by Kounis syndrome within approximately one month-an uncommon presentation. One episode manifested as chest pain accompanied by tongue swelling, and was diagnosed as Type II Kounis syndrome and treated with cetirizine for anti-allergic purposes. The second episode occurred about one month later with persistent chest pain and recurrent tongue swelling, and coronary angiography confirmed acute coronary stent thrombosis. Taken together with the allergic manifestation (tongue swelling) accompanying both events, the second episode fulfilled the criteria for Type III Kounis syndrome. Subsequently, we performed emergency procedures to open the blocked coronary artery and administered glucocorticoid therapy. The patient's symptoms improved. Despite antihistamine therapy with cetirizine in the first episode, this patient still developed subsequent stent-related thrombosis. This case highlights that combined anti-allergic therapy including glucocorticoids may be considered at an early stage for Kounis syndrome patients with unidentified allergens, to mitigate potential allergic-mediated cardiac risk. Nevertheless, we cannot conclude glucocorticoids definitely prevent stent thrombosis, as avoidance of unrecognized allergens may also contribute to clinical improvement.

PMID 42920497
阅读全文 →
PubMedJournal of the American Society for Mass Spectrometry2026-10-23

MALDI MSI Workflow for Pharmaceutical Tablets: Toward a Reproducible Strategy for High-Resolution Imaging.

Lisgara Athina A, Santos-Neto Alvaro A, Charkoftaki Georgia G, Aalizadeh Reza R et al.

Mass spectrometry imaging (MSI) can complement liquid chromatography-mass spectrometry (LC-MS), the gold standard for impurity assessment, by enabling spatial visualization of active pharmaceutical ingredients (APIs), byproducts, and excipients in solid formulations. With new advances in matrix-assisted laser desorption/ionization (MALDI) MSI, critical factors such as ablated spot size, raster speed, and standardized tablet surface preparation still need to be properly addressed. This study presents an innovative sample holder and sample preparation protocol enabling reproducible up to 10-μm step size acquisition for MSI analysis of tablets. The workflow was validated by embedding several commercial tablets containing various APIs in blocks with epoxy resin, then transversally cut them to expose their surfaces. Following this, the tablet surfaces were trimmed using a cryostat and subsequently polished with lapping diamond films to achieve flat and even surfaces. The tablets were then placed in a custom metal holder for MALDI-trapped ion mobility spectrometry (TIMS)-MSI analysis using a timsTOF fleX. The optimized protocol provides high-quality sample preparation and avoids loss of laser focus, enabling high-throughput analysis with high sensitivity for tablet imaging. This robustness was essential for spatial resolution measurements using the Smartbeam 3D, where precise initial focusing is required to preserve data quality across imaging areas. Consistent high signal sensitivity was achieved for single pixels in 10 mg cetirizine or 20 mg famotidine tablets and digoxin fragments were detected in a 0.25 mg/130 mg tablet. This approach provides an important tool for pharmaceutical development by enabling reliable, high-resolution spatial analysis of active ingredients and impurities in solid dosage forms. Collision cross section (CCS) values from reference standards and tablets, as well as MS/MS data were used for confident identification. LC-MS-based workflows remain essential for quantitative analysis of impurity assessment, while infrared spectroscopy (IR) and nuclear magnetic resonance (NMR) can support formulation level characterization. MALDI-TIMS-MSI complements these approaches by adding direct spatial localization of APIs and API-related molecular features within the tablet matrix.

PMID 42916754
阅读全文 →
PubMedUrologia internationalis2026-10-20

Efficacy of cetirizine, tamsulosin and their combination as medical expulsive therapy for distal ureteral stones: a prospective randomized study.

Hasan Ahmed Mahmoud AM, Ahmed Amr Alameldeen AA, Sayed Reham Farouk RF, AbdelRazek Mostafa M

Background The management of ureteral stones, particularly those measuring less than 10 mm, has garnered considerable attention in urological research, with the goal of enhancing non-invasive treatment methods. Medical expulsive therapy is notable for its low invasiveness and cost. To assess the efficacy and safety of tamsulosin alone, cetirizine alone, as well as their combination in treating distal ureteric stones sized 5-10 mm. Between March 2021 and March 2024, patients presented with lower ureteral stones 5-10 mm were randomly assigned to four groups: group A (121 patients) took tamsulosin 0.4 mg; group B (120 patients) took cetirizine 5 mg; group C (119 patients) took a combination of tamsulosin 0.4 mg and cetirizine 5 mg; and group D (120 patients) received analgesics on demand as a control group. We evaluated stone passage rates, time required for stone expulsion, total analgesic dosage, and any recorded side effects. All outcomes were recorded and analyzed accordingly. Group C exhibited the highest rate of stone expulsion among all groups (85.8% vs. 67%, 55%, and 25% in groups A, B, and D respectively, p = 0.0001). Group C had a substantially shorter time required for stone expulsion in comparison with groups A, B, and D (13.15 ± 5.3 days vs. 14.95 ± 6.95, 17.57 ± 6.21, and 20.94 ± 5.58 days respectively, p < 0.0001). A statistically significant reduction in the total analgesic requirements was demonstrated in group C (p < 0.0001). Except for retrograde ejaculation which was evident in groups A and C (40 %, 37.7 % respectively versus 0% in the other groups, p < 0.0001), no substantial variations regarding the side effects were observed among the groups. Combined therapy with tamsulosin and cetirizine significantly improves stone expulsion rate, shortens expulsion time, and reduces analgesic requirements compared with either therapy alone.

PMID 42900654
阅读全文 →
PubMedThe Journal of allergy and clinical immunology2026-10-16

Comparative efficacy and safety of antihistamines, increased antihistamine dosing, and antihistamine adjuncts for chronic urticaria: a systematic review, dose-response, and network meta-analysis of randomized trials.

Chu Alexandro W L AWL, Zhao Irene X IX, Rayner Daniel G DG, Guyatt Gordon H GH et al.

Chronic urticaria is a common immune-mediated condition characterized by wheals (itch and hives), angioedema, or both, lasting for greater than six weeks. It is managed with H1 antihistamines as the first-line therapy. Fundamental unresolved questions remain regarding the comparative benefits and harms of antihistamines and their adjuncts, and of H1 antihistamine dose-escalation. To analyze the comparative benefits and harms of antihistamines and their adjuncts (H2 blockers or montelukast), and of H1 antihistamine dose-escalation. As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random effects network and dose-response meta-analyses addressed urticaria activity (composed of itch and wheal scores), angioedema activity, urticaria-related quality of life, and harms including sedation. The GRADE approach informed certainty of evidence ratings. CRD42022367280. 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, fexofenadine, and levocetirizine are among the most effective in improving overall urticaria activity, urticaria-related quality of life, and sleep disturbance. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also among the most effective in improving urticaria-related quality of life. Escalating from a single to quadruple daily dose may yield diminishing additional benefit. Second-generation agents as a class may be more effective than first-generation agents in improving urticaria activity and sleep disturbance. Sedation risk likely increases with higher doses, with first-generation agents (e.g., diphenhydramine, hydroxyzine) and doxepin among the most sedating; cetirizine, ketotifen, levocetirizine, and rupatadine among the intermediate sedating; and bepotastine, bilastine, desloratadine, ebastine, fexofenadine, and loratadine among the least sedating. Adding montelukast (moderate certainty) or an H2 blocker (very low certainty) to a second-generation agent may further reduce urticaria activity. For chronic urticaria, second-generation agents differ in their efficacy and safety. First-generation agents are less beneficial and more harmful. Escalating to higher daily doses may provide additional benefits but likely increases sedation.

PMID 42887704
阅读全文 →
PubMedFrontiers in medicine2026-10-13

Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review.

Yu Peng P, Wei Fenglei F

An 8-year-11-month-old girl with severe atopic dermatitis had previously received treatments including topical hydrocortisone butyrate, pimecrolimus, tacrolimus, hormone ointment encapsulation, and narrowband ultraviolet B (NB-UVB) phototherapy. She also took oral antihistamines such as cetirizine and loratadine, but these interventions provided limited relief, and her pruritus persisted. In August 2023, she began dupilumab therapy with a 400 mg subcutaneous loading dose, followed by 200 mg subcutaneous injections every two weeks. Vitiligo developed three months after dupilumab initiation in this child with severe atopic dermatitis and improved with combination therapy while dupilumab was continued. Together with previously published reports, this observation supports a possible temporal association between dupilumab exposure and vitiligo development; however, causality cannot be established from the currently available evidence.

PMID 42865691
阅读全文 →

注册免费账户还可查看另外 1876 篇文献

免费注册查看全部文献 →

了解更多cetirizine